Pfizer, Haleon and Sensodyne
Pfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says
Sept 30 (Reuters) - Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon, a bookrunner said on Monday. The proposed sale will reduce the top shareholder's interest in Sensodyne-maker Haleon to 16.
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer will receive all net proceeds from the offering, it said. In a separate statement, Haleon said it agreed to make an off-market purchase of approximately 230 million pounds ($307.7 million) worth of its ordinary shares from Pfizer.
Pfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner
Pfizer intends to sell about 540 million shares in British consumer healthcare company Haleon , a bookrunner said on Monday, ...
bovnews6h
Pfizer Inc (PFE) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?
On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.09 which represents a slight increase of $0.12 or 0.41% from the prior close of $28.97. The stock opened at $29.02 and ...
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Medscape16h
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
STAT4d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Yahoo Finance21h
Pipeline Moves: Pfizer scores in Phase II cancer cachexia trial
This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer ...